Atlas Venture Fund X L.P. 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:31 pm Sale |
2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 4,173,216 6.400% |
-794,898 (-16.00%) |
Filing |
| 2024-02-09 4:03 pm Sale |
2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 4,968,114 8.400% |
-98,811 (-1.95%) |
Filing |
| 2023-02-14 4:28 pm Sale |
2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 5,066,925 9.200% |
-696,087 (-12.08%) |
Filing |
| 2022-02-11 5:09 pm Sale |
2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 5,763,012 11.200% |
-2,185,970 (-27.50%) |
Filing |
| 2021-02-16 5:27 pm Purchase |
2020-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 7,948,982 17.900% |
7,948,982 (New Position) |
Filing |